Arcellx - Bathi saben saham sajrone rolas wulan pungkasan ACLX

Positive trial results for CAR-T therapy in myeloma are creating current momentum, yet Arcellx operational processes rely on external CRO and CMO contractors. The fundamental EPS TTM metric visualizes capital accumulation phases, where -4.05 shows the value of this parameter. This underscores the status of an innovator creating safe cell engineering to save patients in critical conditions.

ACLX Bathi resik saben siji saham sajrone rolas wulan pungkasan Arcellx Therapeutics (28.04.2023 - 09.05.2026)

Ringkesan rincian data analitis Arcellx Inc (ACLX)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega Arcellx|ACLX - Bagan rega target

- rincian nilai pasar emiten:

Nilai pasar Arcellx, Inc.|ACLX - Total Nilai Perusahaan

- data nilai buku modal saham:

Aset Bersih saben Siji Saham Arcellx|ACLX - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku arcellx.com|ACLX - Total Aset Bisnis

- rincian utang lan likuiditas:

- data bathi lan kelipatan valuasi:

ACLX - Bathi resik perusahaan|Bathi sing dikarepake Arcellx|ACLX - Rasio rega marang bathi|Prakiraan rega marang bathi Arcellx, Inc.|ACLX - Rasio P/E diaturake wutah|Pangali EV/EBITDA Arcellx, Inc.|ACLX - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Arcellx|ACLX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan arcellx.com|ACLX - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Arcellx

Analisis umum perusahaan:Arcellx (ACLX)

EPS TTM is calculated as the ratio of total annual net income to the number of shares outstanding, allowing for an assessment of the business's real profitability without market noise. By analyzing the EPS TTM dynamics of Arcellx (ACLX), an investor can see how R&D efficiency and the logistical stability of CAR-T therapy manufacturing partners convert into actual financial results per share of capital.

Analisis pesaing